Article ID Journal Published Year Pages File Type
8528103 Clinical Therapeutics 2018 14 Pages PDF
Abstract
From the scarce data available, the consequences of switching between reference product mAbs and their biosimilar(s) in the oncology setting are as yet unknown. Additional clinical evidence from well-designed switching studies is needed to guide switching decisions.
Keywords
Related Topics
Health Sciences Medicine and Dentistry Medicine and Dentistry (General)
Preview
Monoclonal Antibody Biosimilars in Oncology: Critical Appraisal of Available Data on Switching
Authors
, , , , , , , , , ,